Literature DB >> 33649538

The RanBP2/RanGAP1-SUMO complex gates β-arrestin2 nuclear entry to regulate the Mdm2-p53 signaling axis.

Elodie Blondel-Tepaz1,2,3, Marie Leverve1,2,3, Badr Sokrat4,5, Justine S Paradis5,6, Milena Kosic7, Kusumika Saha1,2,3, Cédric Auffray1,2,3, Evelyne Lima-Fernandes1,2,3, Alessia Zamborlini8, Anne Poupon9, Louis Gaboury5,10, Jane Findlay11, George S Baillie11, Hervé Enslen1,2,3, Michel Bouvier5,6, Stéphane Angers7, Stefano Marullo1,2,3, Mark G H Scott12,13,14.   

Abstract

Mdm2 antagonizes the tumor suppressor p53. Targeting the Mdm2-p53 interaction represents an attractive approach for the treatment of cancers with functional p53. Investigating mechanisms underlying Mdm2-p53 regulation is therefore important. The scaffold protein β-arrestin2 (β-arr2) regulates tumor suppressor p53 by counteracting Mdm2. β-arr2 nucleocytoplasmic shuttling displaces Mdm2 from the nucleus to the cytoplasm resulting in enhanced p53 signaling. β-arr2 is constitutively exported from the nucleus, via a nuclear export signal, but mechanisms regulating its nuclear entry are not completely elucidated. β-arr2 can be SUMOylated, but no information is available on how SUMO may regulate β-arr2 nucleocytoplasmic shuttling. While we found β-arr2 SUMOylation to be dispensable for nuclear import, we identified a non-covalent interaction between SUMO and β-arr2, via a SUMO interaction motif (SIM), that is required for β-arr2 cytonuclear trafficking. This SIM promotes association of β-arr2 with the multimolecular RanBP2/RanGAP1-SUMO nucleocytoplasmic transport hub that resides on the cytoplasmic filaments of the nuclear pore complex. Depletion of RanBP2/RanGAP1-SUMO levels result in defective β-arr2 nuclear entry. Mutation of the SIM inhibits β-arr2 nuclear import, its ability to delocalize Mdm2 from the nucleus to the cytoplasm and enhanced p53 signaling in lung and breast tumor cell lines. Thus, a β-arr2 SIM nuclear entry checkpoint, coupled with active β-arr2 nuclear export, regulates its cytonuclear trafficking function to control the Mdm2-p53 signaling axis.

Entities:  

Year:  2021        PMID: 33649538     DOI: 10.1038/s41388-021-01704-w

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  47 in total

1.  Beta-arrestin 2: a receptor-regulated MAPK scaffold for the activation of JNK3.

Authors:  P H McDonald; C W Chow; W E Miller; S A Laporte; M E Field; F T Lin; R J Davis; R J Lefkowitz
Journal:  Science       Date:  2000-11-24       Impact factor: 47.728

Review 2.  β-Arrestins: Multitask Scaffolds Orchestrating the Where and When in Cell Signalling.

Authors:  Stéphane A Laporte; Mark G H Scott
Journal:  Methods Mol Biol       Date:  2019

Review 3.  The Diverse Roles of Arrestin Scaffolds in G Protein-Coupled Receptor Signaling.

Authors:  Yuri K Peterson; Louis M Luttrell
Journal:  Pharmacol Rev       Date:  2017-07       Impact factor: 25.468

4.  Activation and targeting of extracellular signal-regulated kinases by beta-arrestin scaffolds.

Authors:  L M Luttrell; F L Roudabush; E W Choy; W E Miller; M E Field; K L Pierce; R J Lefkowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-20       Impact factor: 11.205

5.  PTEN controls glandular morphogenesis through a juxtamembrane β-Arrestin1/ARHGAP21 scaffolding complex.

Authors:  Arman Javadi; Ravi K Deevi; Emma Evergren; Elodie Blondel-Tepaz; George S Baillie; Mark Gh Scott; Frederick C Campbell
Journal:  Elife       Date:  2017-07-27       Impact factor: 8.140

6.  Regulation of receptor fate by ubiquitination of activated beta 2-adrenergic receptor and beta-arrestin.

Authors:  S K Shenoy; P H McDonald; T A Kohout; R J Lefkowitz
Journal:  Science       Date:  2001-10-04       Impact factor: 47.728

7.  beta-arrestin 2 oligomerization controls the Mdm2-dependent inhibition of p53.

Authors:  Cédric Boularan; Mark G H Scott; Karima Bourougaa; Myriam Bellal; Emmanuel Esteve; Alain Thuret; Alexandre Benmerah; Marc Tramier; Maité Coppey-Moisan; Catherine Labbé-Jullié; Robin Fåhraeus; Stefano Marullo
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-05       Impact factor: 11.205

8.  Subcellular localization of beta-arrestins is determined by their intact N domain and the nuclear export signal at the C terminus.

Authors:  Ping Wang; Yalan Wu; Xin Ge; Lan Ma; Gang Pei
Journal:  J Biol Chem       Date:  2003-01-21       Impact factor: 5.157

9.  Arrestins as regulatory hubs in cancer signalling pathways.

Authors:  Hervé Enslen; Evelyne Lima-Fernandes; Mark G H Scott
Journal:  Handb Exp Pharmacol       Date:  2014

10.  Manifold roles of β-arrestins in GPCR signaling elucidated with siRNA and CRISPR/Cas9.

Authors:  Louis M Luttrell; Jialu Wang; Bianca Plouffe; Jeffrey S Smith; Lama Yamani; Suneet Kaur; Pierre-Yves Jean-Charles; Christophe Gauthier; Mi-Hye Lee; Biswaranjan Pani; Jihee Kim; Seungkirl Ahn; Sudarshan Rajagopal; Eric Reiter; Michel Bouvier; Sudha K Shenoy; Stéphane A Laporte; Howard A Rockman; Robert J Lefkowitz
Journal:  Sci Signal       Date:  2018-09-25       Impact factor: 9.517

View more
  3 in total

1.  Isolation of a Human Betaretrovirus from Patients with Primary Biliary Cholangitis.

Authors:  Mariam Goubran; Weiwei Wang; Stanislav Indik; Alexander Faschinger; Shawn T Wasilenko; Jasper Bintner; Eric J Carpenter; Guangzhi Zhang; Paulo Nuin; Georgina Macintyre; Gane K-S Wong; Andrew L Mason
Journal:  Viruses       Date:  2022-04-24       Impact factor: 5.818

2.  Control of the Mdm2-p53 signal loop by β-arrestin 2: The ins and outs.

Authors:  Elodie Blondel-Tepaz; Hervé Enslen; Mark G H Scott
Journal:  Oncotarget       Date:  2021-12-21

3.  A Novel Splice Variant of BCAS1 Inhibits β-Arrestin 2 to Promote the Proliferation and Migration of Glioblastoma Cells, and This Effect Was Blocked by Maackiain.

Authors:  Yun-Hua Kuo; Huey-Shan Hung; Chia-Wen Tsai; Shao-Chih Chiu; Shih-Ping Liu; Yu-Ting Chiang; Woei-Cherng Shyu; Shinn-Zong Lin; Ru-Huei Fu
Journal:  Cancers (Basel)       Date:  2022-08-11       Impact factor: 6.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.